Phase I trial to evaluate safety, pharmacokinetics, and efficacy of sorafenib combined with docetaxel in patients with advanced, refractory solid tumors

被引：0
|
作者：
Awada, A.
Hendlisz, A.
Whenham, N.
Gil, T.
Christensen, O.
Lathia, C.
Bartholomeus, S.
Delabaye, I.
De Valeriola, D.
Brendel, E.
Delaunoit, T.
Piccart, M.
机构：
[1] Jules Bordet Inst, Brussels, Belgium
[2] Bayer Pharmaceut Corp, West Haven, CT USA
[3] Bayer HealthCare, Wuppertal, Germany
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [11] A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors
    Iqbal, Syma
    Lenz, Heinz-Josef
    Gandara, David R.
    Shibata, Stephen I.
    Groshen, Susan
    Synold, Timothy W.
    Newman, Edward M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 85 - 91
  • [12] A Phase I Trial of Bexarotene in Combination With Docetaxel in Patients With Advanced Solid Tumors
    Malik, Shakun M.
    Collins, Brian
    Pishvaian, Michael
    Ramzi, Pari
    Marshall, John
    Hwang, Jimmy
    CLINICAL LUNG CANCER, 2011, 12 (04) : 231 - 236
  • [13] A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors
    Gabrail, Nashat Y.
    Tolcher, Anthony
    Alese, Olatunji B.
    Cecchini, Michael
    Manish, Patel
    Park, Haeseong
    Berlin, Jordan
    Hamilton, Erika P.
    Huang, Yingjie
    Lu, Lingmin
    Wang, Jianming
    Shi, Michael
    Tong, Ming F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [14] A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
    Ghalib, Mohammad H.
    Pulla, Mariano Provencio
    Luken, Maria J. De Miguel
    de Juan, Virginia Calvo
    Chaudhary, Imran
    Hammami, M. Bakri
    Vikash, Sindhu
    Maitra, Radhashree
    Martinez, Sara
    Kahatt, Carmen
    Extremera, Sonia
    Fudio, Salvador
    Goel, Sanjay
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (05) : 481 - 491
  • [15] Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors
    Duran, Ignacio
    Hotte, Sebastien J.
    Hirte, Holger
    Chen, Eric X.
    MacLean, Martha
    Turner, Sandra
    Duan, Lixia
    Pond, Gregory R.
    Lathia, Chetan
    Walsh, Scott
    Wright, John J.
    Dancey, Janet
    Siu, Lillian L.
    CLINICAL CANCER RESEARCH, 2007, 13 (16) : 4849 - 4857
  • [16] A phase I trial of riluzole and sorafenib in patients with advanced solid tumors and melanoma.
    Mehnert, Janice M.
    Semlani, Neha
    Wen, Yvonne
    Tan, Antoinette R.
    Moss, Rebecca Anne
    Adams, Shari
    Stein, Mark N.
    Ross, Mikel
    Kane, Michael P.
    Gibbon, Darlene
    Wright, John Joseph
    Aisner, Joseph
    Chen, Suzie
    Goydos, James S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [17] Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors
    Nemunaitis, J
    Eager, R
    Twaddell, T
    Corey, A
    Sekar, K
    Tkaczuk, K
    Thompson, J
    Hoff, PM
    Pazdur, R
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) : 3423 - 3434
  • [18] Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial
    Jaremtchuk, AV
    Zabra, JJ
    Ferro, A
    Aman, EF
    Alvarez, R
    Arroyo, G
    Marmissolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S290 - S290
  • [19] A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Ryoo, Baek-Yeol
    Huang, Dennis Chin-Lun
    Schnell, David
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Cheng, Ann-Lii
    LIVER CANCER, 2018, 7 (02) : 165 - 178
  • [20] A phase I trial of motexafin gadolinium with docetaxel in advanced solid tumors
    Pandya, Kishan J.
    Phan, See-Chun
    ANNALS OF ONCOLOGY, 2004, 15 : 107 - 108
12345